[schoonder]

Phil, since t-dm1 doesn't cross bb barrier and drug's effectiveness prolonging life, and thus increasing possibility of disease metastisizing into brain, I'm somewhat surprised that Genentech which is conducting so many clinical trials with this product isn't conducting one in intrathecal setting. Understand that a number of patients with their oncologists on this Board are conducting some tests which require huge doses of herceptin, not sure why t-dm1 which has a proven trackrecord to help fight mBC at other loci, wouldn't be effective in brain. Do you know if Genentech is contemplating such evaluation?